The Zhitong Finance App learned that Ali Health (00241) fell more than 4%, hitting a new low in the new year. As of press release, there was a decrease of 4.01% to HK$4.55, with a turnover of HK$61,22,500.

According to the news, Ali Health previously released its annual results, recording an annual profit of 533 million yuan attributable to the owners of the parent company, and a loss of 266 million yuan for the same period last year. During the period, revenue was 26.763 billion yuan, up 30.06% year on year; gross profit was 5.701 billion yuan, up 38.79% year on year.

According to management guidelines, FY2024 will achieve double-digit revenue growth and a slight net profit margin improvement, according to management guidelines. The bank lowered its group revenue forecast to reflect double-digit revenue growth guidance. The target price was lowered from HK$12 to HK$9.5, mainly due to slower revenue growth guidelines.

Goldman Sachs, on the other hand, lowered Ali Health's revenue growth rate for fiscal year 2024 to 17%, and lowered Ali Health's target price by 4% from HK$6.7 to HK$6.4 to reflect changes in estimates and foreign exchange assumptions, and maintain a “neutral” rating.